Document Detail

Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
MedLine Citation:
PMID:  22058419     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Erlotinib has demonstrated survival benefit in patients with not only adenocarcinoma but also squamous cell carcinoma. Epidermal growth factor receptor-tyrosine kinase inhibitors are more effective in Asian populations, including the Japanese than in western populations. However, a higher incidence of interstitial lung disease has been reported as a fatal adverse event in the Japanese population. There is little data on erlotinib for Japanese patients with pretreated squamous cell carcinoma.
METHODS: Between January 2004 and October 2010, we retrospectively evaluated the efficacy and toxicity of erlotinib administered as the first epidermal growth factor receptor-tyrosine kinase inhibitors for 41 Japanese patients with pretreated squamous cell carcinoma. Patients with pre-existing interstitial lung disease were carefully excluded by several examinations including high-resolution computed tomography.
RESULTS: The response rate and disease control rate were 9.7% [95% confidence interval: 2.7-23.1%) and 43.9% (95% confidence interval: 28.5-60.2%], respectively. Median time to treatment failure and overall survival were 2.2 months (95% confidence interval: 1.0-2.8 months) and 11.0 months (95% confidence interval: 5.7-15.7 months), respectively. Interstitial lung disease (Grade 5) was observed in one (2.4%) patient. Patients with Grade 0-1 skin rashes vs. patients with Grades 2-3 exhibited disease control rates of 28 vs. 83% (P = 0.0017), and median time to treatment failure of 1.2 months vs. 3.4 months (P = 0.0099).
CONCLUSIONS: Erlotinib has moderate efficacy for pretreated squamous cell carcinoma in Japanese patients. A higher grade of skin rash was associated with clinical benefit. Careful exclusion of pre-existing interstitial lung disease can minimize the occurrence of interstitial lung disease.
Akito Hata; Nobuyuki Katakami; Kei Kunimasa; Hiroshige Yoshioka; Shiro Fujita; Reiko Kaji; Ryo Tachikawa; Keisuke Tomii; Yukihiro Imai; Masahiro Iwasaku; Tadashi Ishida
Related Documents :
20738899 - Is there a role for surgery in stage iiia-n2 non-small cell lung cancer?
20466499 - Msct multi-criteria: a novel approach in assessment of mediastinal lymph node metastase...
24101169 - Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positi...
10871819 - Restaging with gallium scan identifies chemosensitive patients and predicts survival of...
16398809 - Complete resection via medial sternotomy for non-small cell lung cancer in the right up...
24746579 - Radiation therapy: a major factor in the five-year survival analysis of women with brea...
12322709 - Mopp chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of...
19028339 - Current state-of-the-art for concurrent chemoradiation.
16478629 - Intraarterial cisplatin/nedaplatin and intravenous 5-fluorouracil with concurrent radia...
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2011-11-03
Journal Detail:
Title:  Japanese journal of clinical oncology     Volume:  41     ISSN:  1465-3621     ISO Abbreviation:  Jpn. J. Clin. Oncol.     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-30     Completed Date:  2012-01-23     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0313225     Medline TA:  Jpn J Clin Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1366-72     Citation Subset:  IM    
Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 2-2 Minatojima-minamimachi, Chuo-ku, Kobe 650-0047, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Carcinoma, Squamous Cell / drug therapy*
Dose-Response Relationship, Drug
Drug Eruptions / etiology
Lung Diseases, Interstitial / chemically induced,  prevention & control
Lung Neoplasms / drug therapy*
Middle Aged
Patient Selection
Protein Kinase Inhibitors / adverse effects,  therapeutic use*
Quinazolines / adverse effects,  therapeutic use*
Receptor, Epidermal Growth Factor / antagonists & inhibitors*
Retrospective Studies
Smoking / adverse effects
Survival Analysis
Reg. No./Substance:
0/Protein Kinase Inhibitors; 0/Quinazolines; EC, Epidermal Growth Factor; J4T82NDH7E/erlotinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multiple human papillomavirus infections and type competition in men.
Next Document:  Pivotal advance: peritoneal cavity B-1 B cells have phagocytic and microbicidal capacities and prese...